| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 09/07/2004 | US6787549 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder |
| 09/07/2004 | US6787538 Hormone replacement therapy; agonists, antagonists; antiestrogens with little to no intrinsic estrogenicity |
| 09/07/2004 | US6787342 Paste formulations |
| 09/02/2004 | WO2004074840A1 Method for the quantitative measurement of ligands in the sample of dissolved binding proteins |
| 09/02/2004 | WO2004074428A2 Treatment of metabolic disorders |
| 09/02/2004 | WO2004074345A2 Carbonate esters of polyethylene glycol activated by means of oxalate esters |
| 09/02/2004 | WO2004061091A3 Insulin producing cells |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171690 Use of protein essential aminoacids to treat amenorrhea and related disorders |
| 09/02/2004 | US20040171660 Single dose aromatase inhibitor for treating infertility |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171607 Chemical compounds |
| 09/02/2004 | US20040171597 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 09/02/2004 | US20040171595 new process for the preparation of a key intermediate |
| 09/02/2004 | US20040171534 chimeric analogs include a hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170713 To promote good health and as a dietary additive |
| 09/02/2004 | US20040170673 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | CA2515612A1 Activated polyethylene glycol esters |
| 09/01/2004 | EP1452176A1 Insulin resistance improving agents |
| 09/01/2004 | EP1451172A1 Therapeutic isoquinoline compounds |
| 09/01/2004 | EP1451166A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451158A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451157A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1450786A1 Isoflavone concentrate and method for production thereof |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450772A1 Micronized film-forming powder comprising an active substance |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1127058B1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 09/01/2004 | EP1123008A4 Preparation and use of solidified oils |
| 09/01/2004 | CN1526020A Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins. |
| 09/01/2004 | CN1525978A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/01/2004 | CN1525972A Hetero-bicyclic crf antagonists |
| 09/01/2004 | CN1524857A Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 09/01/2004 | CN1524850A Histone de-acetylase inhibitor, preparation and application of pharmaceutical preparations of the same |
| 09/01/2004 | CN1164579C Thiazole and oxazole derivatives and their pharmaceutical use |
| 09/01/2004 | CN1164317C Revival pill for treating woman diseases |
| 08/31/2004 | US6784291 Splice-region antisense composition and method |
| 08/31/2004 | US6784170 Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one |
| 08/31/2004 | US6783761 Hormone inhibitors for inducing antibodies against gonadotropin-releasing hormone, comprises fusion peptide of helper t-cell peptide epitope and immunomimic peptide epitope |
| 08/26/2004 | WO2004072643A2 Diagnostics and therapeutics for diseases associated with glucagon-like peptide 2 receptor (glp2r) |
| 08/26/2004 | WO2004072044A2 Urea and thiourea derivatives |
| 08/26/2004 | WO2004071529A2 Uses of anti-insulin-like growth factor i receptor antibodies |
| 08/26/2004 | WO2003055440A3 Compositions and methods for the treatement of immune related diseases |
| 08/26/2004 | US20040167176 Tricyclic compounds useful as angiotensin II agonists |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | US20040167127 atherosclerosis; antiarthritic agents; antidiabetic agents; cardiovascular disorders; autoimmune diseases; multiple sclerosis; chronic obstructive pulmonary disease |
| 08/26/2004 | CA2515589A1 Urea and thiourea derivatives |
| 08/26/2004 | CA2514231A1 Uses of anti-insulin-like growth factor i receptor antibodies |
| 08/25/2004 | EP1449842A1 Process for the preparation of pyrazolopyridine tartrates |
| 08/25/2004 | EP1448993A2 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin |
| 08/25/2004 | EP1448591A1 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 08/25/2004 | EP1448559A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
| 08/25/2004 | EP1448526A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| 08/25/2004 | EP1448524A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448221A1 Injection solution comprising an lhrh antagonist |
| 08/25/2004 | EP1448216A2 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 08/25/2004 | EP1448175A1 Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate |
| 08/25/2004 | EP1448171A2 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1150977B1 Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| 08/25/2004 | CN1524090A Modified insulin with reduced immunogenicity |
| 08/25/2004 | CN1524082A Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl idase inhibitors for the treatment or prevention of diabetes |
| 08/25/2004 | CN1523992A Compositions and methods for treating amyloidosis |
| 08/25/2004 | CN1523989A Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/25/2004 | CN1163260C Ionic molecular conjugates of biodergaable polyesters and bioactive polypeptides |
| 08/24/2004 | US6780972 Reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger; forming a free peptide; and then forming the desired acid addition salt of the peptide |
| 08/24/2004 | US6780884 Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them |
| 08/24/2004 | US6780869 Selective inhibitor of cox-2; antiinflammatory agent |
| 08/24/2004 | US6780855 Treating a patient suffering from an estrogen dependent-disease |
| 08/24/2004 | US6780854 Orally active androgens |
| 08/24/2004 | US6780609 High bone mass gene of 1.1q13.3 |
| 08/24/2004 | CA2290252C Process and intermediates for growth hormone secretagogues |
| 08/19/2004 | WO2004069866A1 Therapeutic molecules |
| 08/19/2004 | WO2004069798A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 08/19/2004 | WO2004056365A3 Derivatives of aryl-quinazoline/aryl-2amino-phenyl methanone which promote the release of parathyroid hormone |
| 08/19/2004 | WO2004043994A3 A retro-inverso gonadotropin-releasing hormone peptide and vaccine composition |
| 08/19/2004 | WO2003092585A3 Controlled release compositions of estradiol metabolites |
| 08/19/2004 | WO2003077834A3 Central airway administration for systemic delivery of therapeutics |
| 08/19/2004 | US20040162388 Activated polyethylene glycol esters |
| 08/19/2004 | US20040162331 Heterocylic amines used as antidiabetic or hyperglycemic agents |
| 08/19/2004 | US20040162304 Estrogen receptor modulators |
| 08/19/2004 | US20040162290 For therapy of cancer, benign prostatic hypertrophy or myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty, lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism |
| 08/19/2004 | US20040162274 Inhibition of steroid synthesis by use of progesterone or a progesterone receptor agonist |
| 08/19/2004 | US20040162233 Administering agent in form of iodinated organic compound containing iodinated protein and/or its low molecular component which includes at least one of the following amino acids: phenylalanine and tryptophan |
| 08/19/2004 | CA2515717A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 08/19/2004 | CA2514071A1 Therapeutic molecules |
| 08/18/2004 | EP1447402A1 Quinoline compound |
| 08/18/2004 | EP1446733A2 Glycosylphosphatidylinositol containing polypeptides |
| 08/18/2004 | EP1446161A2 Medicinal combination of biguanine (metformin) and arginine |
| 08/18/2004 | EP1446144A2 The use of leptin in infertility |